A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia
Latest Information Update: 08 Nov 2021
Price :
$35 *
At a glance
- Drugs A 0001 (Primary)
- Indications Friedreich's ataxia
- Focus Pharmacodynamics
- 11 Jun 2011 Results released in an Edison Pharmaceuticals media release.
- 11 Jun 2011 Primary endpoint 'Disposition Index of Glucose Regulation assessed via intravenous glucose tolerance testing ' has not been met, according to results from an Edison Pharmaceuticals media release
- 21 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.